Mirvetuximab soravtansine-gynx - Biologic Drug Details

Summary for mirvetuximab soravtansine-gynx

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for mirvetuximab soravtansine-gynx Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for mirvetuximab soravtansine-gynx Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for mirvetuximab soravtansine-gynx Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Mirvetuximab Soravtansine-gynx

Introduction

Mirvetuximab soravtansine-gynx, marketed as ELAHERE, is a groundbreaking biologic drug developed by ImmunoGen for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. Here, we delve into the market dynamics and financial trajectory of this innovative therapy.

Clinical Significance and Approval

Mirvetuximab soravtansine-gynx received accelerated approval from the US Food and Drug Administration (FDA) on November 14, 2022, based on the Objective Response Rate (ORR), Tumor Burden (TB), and Duration of Response (DoR) data from the pivotal SORAYA trial[1].

Unmet Medical Needs

The drug addresses a significant unmet medical need, particularly for patients with platinum-resistant ovarian cancer, who have limited treatment options and poor outcomes. Most women with ovarian cancer are diagnosed at Stage III or IV, contributing to high mortality rates[1].

Clinical Trials and Ongoing Studies

In addition to the SORAYA trial, ImmunoGen is conducting two ongoing trials for platinum-sensitive ovarian cancer: the PICCOLO (Phase II) and GLORIOSA (Phase III) studies. These trials are crucial for expanding the drug's clinical benefits and potential market access[1].

Market Forecast and Sales Projections

According to GlobalData, sales of mirvetuximab soravtansine-gynx are expected to reach $615 million by 2029, with a compound annual growth rate (CAGR) of 114%. This robust growth is driven by the drug's clinical performance and the expanding patient pool, particularly in the platinum-sensitive ovarian cancer segment[1].

Financial Performance

In the first full quarter of launch following FDA approval, ImmunoGen generated $29.5 million in ELAHERE net sales for the quarter ended March 31, 2023. Total revenues for the quarter were $49.9 million, significantly driven by ELAHERE sales and other licensing agreements[3].

Quarterly and Annual Financials

• Q1 2023: $29.5 million in ELAHERE net sales, with total revenues of $49.9 million[3].
• 2022 Financials: Total revenues were $108.8 million, with research and development expenses of $213.4 million and a net loss of $222.9 million[2].

Cost and Operating Expenses

The financial reports highlight significant research and development expenses, which are expected given the ongoing clinical trials and development of new agents. For 2022, research and development expenses rose to $213.4 million, while selling, general, and administrative expenses were $116.1 million[2].

Acquisition by AbbVie

In a significant development, AbbVie finalized a deal to acquire ImmunoGen, highlighting the potential long-term revenue growth from ImmunoGen's oncology portfolio, including mirvetuximab soravtansine-gynx. This acquisition is expected to expand the drug's use into earlier lines of therapy and larger patient segments over the next decade[4].

Market Assessment and Competitors

The market assessment for mirvetuximab soravtansine-gynx includes a detailed analysis of its mechanism of action, dosage, and administration, as well as regulatory milestones and developmental activities. The drug competes in a market with other emerging therapies for ovarian cancer, but its unique profile as a first-in-class ADC targeting folate receptor alpha (FRα) positions it favorably[5].

Safety Profile and Clinical Benefits

Mirvetuximab soravtansine-gynx has demonstrated a favorable safety profile, primarily consisting of low-grade ocular and gastrointestinal events with lower rates of grade ≥3 adverse events. Clinically, it has outperformed investigator’s choice chemotherapies in various metrics, including median progression-free survival and overall survival[1].

Clinical Metrics

• Median Progression-Free Survival: 5.6 months vs. 4 months for the investigator’s choice arm.
• Median Overall Survival: 16.5 months vs. 12.8 months for the investigator’s choice arm.
• Objective Response Rates: 42.3% vs. 15.9% for the investigator’s choice arm[1].

Future Market Potential

The future market potential for mirvetuximab soravtansine-gynx is promising, with forecasted sales data indicating significant growth from 2024 to 2032. The drug's potential expansion into earlier lines of therapy and its combination with other treatments, such as Avastin, further enhance its market prospects[5].

Key Takeaways

• Accelerated FDA Approval: Mirvetuximab soravtansine-gynx received FDA approval in November 2022 for treating FRα-positive, platinum-resistant ovarian cancer.
• Strong Sales Projections: Expected to reach $615 million in sales by 2029 with a 114% CAGR.
• Ongoing Clinical Trials: PICCOLO and GLORIOSA trials aim to expand the drug's clinical benefits.
• Acquisition by AbbVie: Positions the drug for long-term revenue growth and expanded market access.
• Favorable Safety Profile: Low-grade adverse events with significant clinical benefits.

FAQs

What is mirvetuximab soravtansine-gynx used for?

Mirvetuximab soravtansine-gynx is used for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

What are the key clinical benefits of mirvetuximab soravtansine-gynx?

The drug has shown improved median progression-free survival, overall survival, and objective response rates compared to investigator’s choice chemotherapies.

What are the expected sales projections for mirvetuximab soravtansine-gynx?

Sales are expected to reach $615 million by 2029, with a compound annual growth rate (CAGR) of 114%.

Who acquired ImmunoGen and what are the implications?

AbbVie acquired ImmunoGen, which is expected to drive long-term revenue growth and expand the drug's use into earlier lines of therapy and larger patient segments.

What ongoing trials are significant for mirvetuximab soravtansine-gynx?

The PICCOLO (Phase II) and GLORIOSA (Phase III) trials are crucial for expanding the drug's clinical benefits and potential market access.

Sources

1. GlobalData: "Immunogen's Mirvetuximab Soravtansine-gynx Sales Projected to Reach $615 Million by 2029"[1].
2. ImmunoGen: "ImmunoGen Reports Recent Progress and 2022 Financial Results"[2].
3. Biospace: "ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results"[3].
4. Pharmaceutical Commerce: "AbbVie Finalizes Deal to Acquire ImmunoGen With its Pipeline of Antibody-Drug Conjugates"[4].
5. GIIR: "Mirvetuximab Soravtansine Market Size, Forecast, and Drug Insight - 2032"[5].

Last updated: 2024-12-22